Mechanisms for inhibition of P2 receptors signaling in neural cells

Molecular Neurobiology

Volumn 31, Issue 1-3, 2005, Pages 65-79

  González, Fernando A ^a   Weisman, Gary A ^b   Erb, Laurie ^b   Seye, Cheikh I ^b   Sun, Grace Y ^b   Velázquez, Betty ^a   Hernández Pérez, Melvin ^a   Chorna, Nataliya E ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b University of Missouri   (United States)

Author keywords

Antagonists; Astrocytes; Astrogliosis; Extracellular nucleotides; Nucleotide receptors; Purinergic signaling

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 CHLORO N 6 METHYLMETHANOCARBA 2' DEOXYADENOSINE 3',5' BISPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 2'(3') O (2,4,6 TRINITROPHENYL)ADENOSINE TRIPHOSPHATE; A 317491; ACETYLSALICYLIC ACID; ACID BLUE 129; ACID BLUE 25; ACID BLUE 80; ACID VIOLET 34; ANTIBODY; AR C 69931 MX; BASILEN BLUE; CIPROFIBROYL COENZYME A; CLOPIDOGREL; COENZYME A; FOCAL ADHESION KINASE; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE P38; MRS 2279; MRS 2409; NAFENOPIN COENZYME A; NF 449; PERIODATE OXIDIZED ADENOSINE TRIPHOSPHATE; PHOSPHOLIPASE C; PROTEIN KINASE C; PURINE P2 RECEPTOR; PURINE P2Y2 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TRICHLOROETHANOL; UNCLASSIFIED DRUG;

ASTROCYTE; BRAIN INJURY; CALCIUM CELL LEVEL; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL REGENERATION; CELL VIABILITY; CONFERENCE PAPER; CYTOSKELETON; DESENSITIZATION; DNA SYNTHESIS; DRUG POTENCY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR SPACE; HUMAN; NERVE CELL; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NONHUMAN; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYNAPTOGENESIS;

EID: 24644439975     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/mn:31:1-3:065     Document Type: Conference Paper

References (91)

1. Eddleston M. and Mucke L. (1993) Molecular profile of reactive astrocytes: implications for their role in neurologic disease. Neuroscience 54, 15-36.
2. Ridet J.L., Malhotra S.K., Privat A., and Gage F.H. (1997) Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20, 570-577.
3. Abbrachio M.P., Brambilla R., Ceturi S., and Cattabeni F. (1999) Signalling mechanisms involved in P2Y receptor-mediated reactive astroglyosis. Prog. Brain Res. 120, 333-342.
4. Neary J.T., Kang Y., Bu Y., Yu E., Akong K., and Peters C.M. (1999) Mitogenic signaling by ATP/P2Y purinergic receptors in astrocytes: involvement of a calcium-independent protein kinase C, extracellular signal-regulated protein kinase pathway distinct from the phosphatidylinositol-specific phospholipase C/calcium pathway. J. Neurosci. 19, 4211-4220.
5. Ralevic V. and Burnstock G. (1998) Receptors for purines and pyrimidines. Pharmacol. Rev. 50, 413-492.
6. Sak K., Boeynaems J.M., and Everaus H. (2003) Involvement of P2Y receptors in the differentiation of haematopoietic cells. J. Leukocyte Biol. 73, 442-447.
7. Khakh B.S., Burnstock G., Kennedy C., et al. (2001) International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev. 53, 107-118.
8. Chizh B.A. and Illes P. (2001) P2X receptors and nociception. Pharmacol. Rev. 53, 553-568.
9. Berchtold S., Ogilvie A.L., Bogdan C., et al. (1999) Human monocyte derived dendritic cells express functional P2X and P2Y receptors as well as ecto-nucleotidases. FEBS Lett. 458, 424-428.
10. Jiang L.H., Kim M., Spelta V., Bo X., Surprenant A., and North R.A. (2003) Subunit arrangement in P2X receptors. J. Neurosci. 23, 8903-8910.
11. North R.A. (2002) Molecular physiology of P2X receptors. Physiol. Rev. 82, 1013-1067.
12. Norenberg W. and Illes P. (2000) Neuronal P2X receptors: localisation and functional properties. Naunyn Schmiedeberg's Arch. Pharmacol. 362, 324-339.
13. Khakh B.S. (2001) Molecular physiology of P2X receptors and ATP signalling at synapses. Nat. Rev. Neurosci. 2, 165-174.
14. Bleehen T. and Keele C.A. (1977) Observations on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 3, 367-377.
15. Ding Y., Cesare P., Drew L., Nikitaki D., and Wood J.N. (2000) ATP, P2X receptors and pain pathways. J. Auton. Nerv. Syst. 81, 289-294.
16. Pubill D., Dayanithi G., Siatka C., et al. (2001) ATP induces intracellular calcium increases and actin cytoskeleton disaggregation via P2x receptors. Cell Calcium 29, 299-309.
17. 7 receptor signalling complex. EMBO J. 20, 6347-6358.
18. Ayyanathan K., Webbs T.E., Sandhu A.K., Athwal R.S., Barnard E.A., and Kunapuli S.P (1996) Cloning and chromosomal localization of the human P2Y1 purinoceptor. Biochem. Biophys. Res. Commun. 218, 783-788.
19. Parr C.E., Sullivan D.M., Paradiso A.M., et al. (1994) Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy. Proc. Natl. Acad. Sci. USA 91, 3275-3279.
20. von Kugelgen I. and Wetter A. (2000) Molecular pharmacology of P2Y-receptors. Naunyn Schmiedeberg's Arch. Pharmacol. 362, 310-323.
21. 15, for AMP and adenosine. J. Biol. Chem. 279, 19,790-19,799.
22. Neary J.T. and Abbracchio M.P (2001) Trophic roles of purines and pyrimidines, in Handbook of Experimental Pharmacology: Purinergic and Pyrimidergic Signalling, Williams M and Abbracchio M, eds., Springer-Verlag, New York, pp. 305-338.
23. 2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. Mol. Neurobiol. in press.
24. o-mediated signal transduction. J. Cell Biol. 153, 491-502.
25. Neary J.T. and Zhu Q. (1994) Signaling by ATP receptors in astrocytes. Neuroreport 5, 1617-1620.
26. King B.F., Neary J.T., Zhu Q., Wang S., Norenberg M.D., and Burnstock G. (1996) P2 purinoceptors in rat cortical astrocytes: expression, calcium-imaging and signalling studies. Neuroscience 74, 1187-1196.
27. 2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J. Biol. Chem. 279, 8212-8218.
28. Paul A., Torrie L.J., McLaren G.J., Kennedy C., Gould G.W., and Plevin R. (2000) P2Y receptor-mediated inhibition of tumor necrosis factor α-stimulated stress-activated protein kinase activity in EAhy926 endothelial cells. J. Biol. Chem. 275, 13,243-13,249.
29. 7 nucleotide receptors that mediate neuroinflammatory responces in astrocytes and microglial cells. Biomed. Res. 14, 47-61.
30. Neary J.T., McCarthy M., Kang Y., and Zuniga S. (1998) Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. Neurosci. Lett. 242, 159-162.
31. Hiratsuka T. and Uchida K. (1973) Preparation and properties of 2′(or 3′)-O-(2,4,6-trinitrophenyl) adenosine 5′-triphosphate, an analog of adenosine triphosphate. Biochim. Biophys. Acta 320, 635-647.
32. Watanabe T. and Inesi G. (1982) The use of 2′,3′-O-(2,4,6- trinitrophenyl) adenosine 5′-triphosphate for studies of nucleotide interaction with sarcoplasmic reticulum vesicles. J. Biol. Chem. 257, 11,510-11,516.
33. 2 receptor. Br. J. Pharmacol. 121, 1445-1453.
34. 2/3 receptors. Mol. Pharmacol. 53, 969-973.
35. 2/3 receptors by 2′, 3′-O-(2,4,6-trinitrophenyl) adenosine 5′-triphosphate (TNP-ATP). Mol. Pharmacol. 58, 1502-1510.
36. Lewis C., Surprenant A., and Evans R. (1998) 2′,3′-O-(2,4,6- trinitrophenyl) adenosine 5′-triphosphate (TNP-ATP)-a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels. Br. J. Pharmacol. 124, 1463-1466.
37. Volonte C., Ciotti M.T., D'Ambrosi N., Lockhart B., and Spedding M. (1999) Neuroprotective effects of modulators of P2 receptors in primary culture of CNS neurones. Neuropharmacology 38, 1335-1342.
38. Cavaliere F., D'Ambrosi N., Sancesario G., Bernardi G., and Volonte C. (2001) Hypoglycaemia-induced cell death: features of neuroprotection by the P2 receptor antagonist basilen blue. Neurochem. Int. 38, 199-207.
39. Cavaliere F., D'Ambrosi N., Ciotti M.T., et al. (2001) Glucose deprivation and chemical hypoxia: neuroprotection by P2 receptor antagonists. Neurochem. Int. 38, 189-197.
40. Cavaliere F., Sancesario G., Bernardi G., and Volonte C. (2002) Extracellular ATP and nerve growth factor intensify hypoglycemia-induced cell death in primary neurons: role of P2 and NGFRp75 receptors. J. Neurochem. 83, 1129-1138.
41. 4 receptor and ischemic cell death: prevention by P2 antagonists. Neuroscience 120, 85-98.
42. D'Ambrosi N., Cavaliere F., Merlo D., Milazzo L., Mercanti D., and Volonte C. (2000) Antagonists of P2 receptor prevent NGF-dependent neuritogenesis in PC12 cells. Neuropharmacology 39, 1083-1094.
43. Zona C., Marchetti C., Volonte C., Mercuri N.B., and Bernardi G. (2000) Effect of P2 purinoceptor antagonists on kainate-induced currents in rat cultured neurons. Brain Res. 882, 26-35.
44. 2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl. Acad. Sci. USA 99, 17,179-17,184.
45. 2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br. J. Pharmacol. 140, 1381-1388.
46. 3 receptors. J. Pharmacol. Exp. Ther. 310, 407-416.
47. Kennedy C., Assis T.S., Currie A.J., and Rowan E.G. (2003) Crossing the pain barrier: P2 receptors as targets for novel analgesics. J. Physiol. 553, 683-694.
48. 7 antagonist, oxidized ATP, in arthritic rats. Neurosci. Lett. 327, 87-90.
49. 7 receptor is not the only target. Br. J. Pharmacol. 140, 441-443.
50. Beigi R.D., Kertesy S.B., Aquilina G., and Dubyak G.R. (2003) Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br. J. Pharmacol. 140, 507-519.
51. 1 receptors. Eur. J. Pharmacol. 470, 1-7.
52. Braun K., Rettinger J., Ganso M., et al. (2001) NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedeberg's Arch. Pharmacol. 364, 285-290.
53. Gargett C. and Wiley J. (1997) The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br. J. Pharmacol. 120, 1483-1490.
54. 7 receptor. J. Med. Chem. 46, 1318-1329.
55. 7 receptor antagonists: probing multiple sites for linking and dimerization. Bioconjug. Chem. 13, 1100-1111.
56. 3 cells and their inhibition by ethanol and trichloroethanol. J. Neurochem. 85, 779-790.
57. Burnstock G. (2002) Potential therapeutic targets in the rapidly expanding field of purinergic signalling. Clin. Med. 2, 45-53.
58. 1 receptor antagonists. FEBS Lett. 536, 145-150.
59. Tuluc F., Bultmann R., Glanzel M., Frahm A.W., and Starke K. (1998) P2-receptor antagonists: IV. Blockade of P2-receptor subtypes and ecto-nucleotidases by compounds related to reactive blue 2. Naunyn Schmiedeberg's Arch. Pharmacol. 357, 111-120.
60. Brown J. and Brown C.A. (2002) Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors. Vasc. Pharmacol. 39, 309-315.
61. 1 antagonist MRS-2179. Cardiovasc. Drug Rev. 21, 67-76.
62. 1 receptor antagonist. Br. J. Pharmacol. 135, 2004-2010.
63. 1 purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques. J. Med. Chem. 45, 962-972.
64. 12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler. Thromb. Vasc. Biol. 23, 357-362.
65. Huang N., Wang D., and Heppel L.A. (1989) Extracellular ATP is a mitogen for 3T3, 3T6, and A431 cells and acts synergistically with other growth factors. Proc. Natl. Acad. Sci. USA 86, 7904-7908.
66. Gonzalez F.A., Wang D., Huang N., and Heppel L.A. (1990) Activation of early events of the mitogenic response by a P2Y purinoceptor with covalently bound 3′-O-(4-benzoyl)-benzoyladenosine 5′-triphosphate. Proc. Natl. Acad. Sci. USA 87, 9717-9721.
67. Wang D., Huang N., Gonzalez F.A., and Heppel L.A. (1991) Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: I. Involvement of protein kinase C-dependent and -independent pathways. J. Cell. Physiol. 146, 473-482.
68. Huang N., Wang D., Gonzalez F.A., and Heppel L.A. (1991) Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenensis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation. J. Cell. Physiol. 146, 483-494.
69. Wang D., Huang N., and Heppel L.A. (1992) Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells. J. Cell. Physiol. 153, 221-233.
70. Neary J.T., Rathbone M.P., Cattabeni F., Abbracchio M.P., and Burnstock G. (1996) Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19, 13-18.
71. Neary J.T., McCarthy M., Cornell-Bell A., and Kang Y. (1999) Trophic signaling pathways activated by purinergic receptors in rat and human astroglia. Prog. Brain Res. 120, 323-332.
72. 2 receptors activate neuroprotective mechanisms in astrocytic cells. J. Neurochem., in press.
73. Ferguson S.S. (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1-24.
74. Krupnick J.G. and Benovic J.L. (1998) The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 38, 289-319.
75. Pitcher J., Lohse M.J., Codina J., Caron M.G., and Lefkowitz R.J. (1992) Desensitization of the isolated β2-adrenergic receptor by β-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry 31, 3193-3197.
76. 2 nucleotide receptor. Mol. Cell. Biochem. 205, 115-123.
77. Ferguson S.S. and Caron M.G. (1998) G protein-coupled receptor adaptation mechanisms. Semin. Cell. Dev. Biol. 9, 119-127.
78. Gonzalez F.A., Gross D.J., Heppel L.A., and Webb W.W. (1988) Studies on the increase in cytosolic free calcium induced by epidermal growth factor, serum, and nucleotides in individual A431 cells. J. Cell. Physiol. 135, 269-276.
79. Gonzalez F.A., Heppel L.A., Gross D.J., Webb W.W., and Parries G. (1988) The rapid desensitization of receptors for platelet derived growth factor, bradykinin and ATP: studies on individual cells using quantitative digital video microscopy. Biochem. Biophys. Res. Commun. 151, 1205-1212.
80. 2+ fluxes in A431 cells. J. Cell. Physiol. 141, 606-617.
81. 2 nucleotide receptor signaling in human monocytic cells: activation, desensitization and coupling to mitogen-activated protein kinases. J. Cell. Physiol. 187, 196-208.
82. 2Y-purinergic receptor-regulated phospholipase C. J. Biol. Chem. 264, 19,535-19,539.
83. Carter T.D., Newton J.S., Jacob R., and Pearson J.D. (1990) Homologous desensitization of ATP-mediated elevations in cytoplasmic calcium and prostacyclin release in human endothelial cells does not involve protein kinase C. Biochem. J. 272, 217-221.
84. 2 nucleotide receptor: consequences of truncation of the C-terminus. J. Biol. Chem. 273, 29,437-29,444.
85. Gonzalez F.A., Ahmed A.H., Lustig K.D., Erb L., and Weisman G.A. (1989) Permeabilization of transformed mouse fibroblasts by 3′-O-(4-benzoyl) benzoyl adenosine 5′-triphosphate and the desensitization of the process. J. Cell. Physiol. 139, 109-115.
86. Gonzalez F.A., Bonapace E., Belzer I., Friedberg I., and Heppel L.A. (1989) Two distinct receptors for ATP can be distinguished in Swiss 3T6 mouse fibroblasts by their desensitization. Biochem. Biophys. Res. Commun. 164, 706-713.
87. North R.A. and Surprenant A. (2000) Pharmacology of cloned P2X receptors. Annu. Rev. Pharmacol. Toxicol. 40, 563-580.
88. Turner J.T., Weisman G.A., and Fedan J.S. (eds.) (1998) The P2 Nucleotide Receptors. Humana, Totowa, NJ.
89. Horton M.A., Lewis D., McNulty K., Pringle J.A., and Chambers T.J. (1985) Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res. 45, 5663-5669.
90. Horton M.A., Taylor M.L., Arnett T.R., and Helfrich M.H. (1991) Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell. Res. 195, 368-375.
91. 3 integrin interactions mediate monocyte activation in press.